Evidence map›Paper›PMID 29385994›Full record

SynthesisBMC cancer2018

Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis.

Zhi-Feng Miao, Xing-Yu Liu, Zhen-Ning Wang, Ting-Ting Zhao, Ying-Ying Xu, Yong-Xi Song, Jin-Yu Huang, Hao Xu, Hui-Mian Xu

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Surgical treatment of gastric adenocarcinoma: what factors influence the prognosis?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025
    Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Efficacy and safety of FLOT regimenResearch in pharmaceutical sciences · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhi-Feng MiaoDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Xing-Yu LiuDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Zhen-Ning WangDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Ting-Ting ZhaoDepartment of Breast Surgery, First Hospital of China Medical University, Shenyang, China.
Ying-Ying XuDepartment of Breast Surgery, First Hospital of China Medical University, Shenyang, China.
Yong-Xi SongDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Jin-Yu HuangDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Hao XuDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China.
Hui-Mian XuDepartment of Surgical Oncology, First Hospital of China Medical University, Shenyang, 110001, China. 13898829926@163.com.

Funding

National Natural Science Foundation of China 81272718National Natural Science Foundation of China 81302125National Natural Science Foundation of China 81372550
6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have reported inconsistent results.

methodsThis study compares the combined use of NAC and surgery with surgery alone for GC by using a meta-analytic approach. We performed an electronic search of PubMed, EmBase, and the Cochrane Library to identify randomized controlled trials (RCTs) on NAC published before Oct 2015. The primary outcome of the studies was data on survival rates for patients with GC. The summary results were pooled using the random-effects model. We included 12 prospective RCTs reporting data on 1538 GC patients.

resultsPatients who received NAC were associated with significant improvement of OS (P = 0.001) and PFS (P < 0.001). Furthermore, NAC therapy significantly increased the incidence of 1-year survival rate (SR) (P = 0.020), 3-year SR (P = 0.011), and 4-year SR (P = 0.001). Similarly, NAC therapy was associated with a lower incidence of 1-year (P < 0.001), 2-year (P < 0.001), 3-year (P < 0.001), 4-year (P = 0.001), and 5-year recurrence rate (P = 0.002). Conversely, patients who received NAC also experienced a significantly increased risk of lymphocytopenia (P = 0.003), and hemoglobinopathy (P = 0.021).

conclusionsThe findings of this study suggested that NAC is associated with significant improvement in the outcomes of survival and disease progression for GC patients while also increasing some toxicity.

Indexed as

Chemotherapy, AdjuvantDisease-Free SurvivalHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalStomach NeoplasmsGastric cancerMeta-analysisNeoadjuvant chemotherapyOverall aurvivalPrognosis

Identifiers

PMID29385994
PMCPMC5793339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.